Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Next Previous
Trial Profile

Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Malignant-atrophic-papulosis
  • Focus Therapeutic Use

Most Recent Events

  • 03 Feb 2026 The primary endpoint has been revised from a time-based radiologic assessment at 6 months to a measurable endpoint defined as the 'Number of Participants With Stable or No New Lesions Based on MRI.' The assessment window has been clarified to evaluate stability or regression of enhancing lesions from baseline through 13 weeks (and up to 72/73 weeks for follow-up consistency), ensuring objective outcome reporting.
  • 16 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 16 Dec 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top